Yasui, Hisateru
Takeno, Atsushi
Hara, Hiroki
Imamura, Hiroshi
Akamatsu, Hiroki
Fujitani, Kazumasa
Nakane, Minoru
Kondoh, Chihiro Nakayama
Yukisawa, Seigo
Nasu, Junichiro
Miyata, Yoshinori
Makiyama, Akitaka
Ishida, Hiroyasu
Yoshida, Norimasa
Matsumura, Eiji
Ishigami, Masato
Sugihara, Masahiro
Ochiai, Atsushi
Doi, Toshihiko
Funding for this research was provided by:
Daiichi Sankyo Company (research funding)
Daiichi-Sankyo (Grant and Personal Fee, honoraria, grants and personal fees)
Dainippon Sumitomo Pharma (grants and personal fees, grants and personal fees)
Merck Biopharma (grants and personal fees)
MSD K.K. (grants and personal fees, grants and personal fees)
Taiho Pharmaceutical (grants and personal fees, honoraria, grants and personal fees)
Chugai Pharmaceutical (grants and personal fees, Personal fees)
Boehringer Ingelheim (grants and personal fees, grants and personal fees)
Ono Pharmaceutical (grants and personal fees, honoraria, Personal fees)
Bayer Yakuhin (grants and personal fees, Personal fe)
AstraZeneca (grants)
Eisai (grants, grants)
Elevar Therapeutics (grants)
Incyte (grants)
Pfizer Japan (grants)
BeiGene (grants)
Astellas Pharma (grants, Personal fees)
GSK (grants)
Eli Lilly Japan (Personal fees, honoraria, grants)
Yakult Honsha (Personal fees)
Sanofi (Personal fees)
Takeda Pharmaceutical Company (Personal fees, Personal fees)
Kyowa Kirin (Personal fees)
Bristol-Myers Squibb (grants and personal fees, honoraria, grants and personal fees)
Novartis (grants and personal fees)
Janssen Pharmaceuticals (grants and personal fees)
Merck Serono (grants)
AbbVie (grants and personal fees)
Pfizer (grants)
Quintiles (grants)
Amgen (personal fees)
Rakuten Medical (Personal fees)
Oncolys BioPharma (Personal fees)
Otsuka Pharmaceutical (Personal fees)
Article History
Accepted: 17 April 2022
First Online: 19 May 2022
Declarations
:
: This study was conducted with the approval of the ethical review board at each study site. All patients provided written informed consent.
: Not applicable.
: The first author (H. Yasui) declares the following conflict of interests: Research fundingĀ and honoraria for lectures from Daiichi Sankyo. H. Hara declares the following conflict of interests: Grants and personal fees from Daiichi Sankyo, Sumitomo Dainippon Pharma, Merck Biopharma, MSD, Taiho Pharma, Chugai Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, Bristol-Myers Squibb, and Bayer; Grants from AstraZeneca, Eisai, Elevar Therapeutics, Incyte, Pfizer, BeiGene, Astellas Pharm, and GSK; Personal fees from Eli Lilly Japan, Yakult Honsha, Sanofi, Takeda Pharmaceutical, and Kyowa Kirin. A. Makiyama declares the following conflict of interests: Honoraria from Eli Lilly Japan, Taiho Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, and Daiichi Sankyo. T. Doi declares the following conflict of interests: Grants and personal fees from MSD, Daiichi Sankyo, Sumitomo Dainippon Pharma, Taiho Pharma, Novartis, Janssen Pharmaceutical, Boehringer Ingelheim, Bristol-Myers Squibb, and Abbvie; Grants from Lilly, Merck Serono Pharmaceutical, Pfizer, Quintiles (IQVIA), and Eisai; Personal fees from Amgen, Takeda Pharmaceutical, Chugai Pharmaceutical, Bayer, Rakuten Medical, Ono Pharmaceutical, Astellas Pharma, Oncolys BioPharma, and Otsuka Pharmaceutical. E. Matsumura, M. Ishigami and M. Sugihara are employees of Daiichi Sankyo. All other authors declare that they have no competing interests.